Vaginal Laser Therapy and Sexual Health in Breast Cancer Survivors Taking Aromatase Inhibitors: A Secondary Analysis

1

This exploratory secondary analysis examined 12-month sexual health outcomes in breast cancer survivors with genitourinary syndrome of menopause who were taking aromatase inhibitors.
2

The double-blind, sham-controlled LIGHT trial randomized 84 participants to five monthly fractional carbon dioxide laser or sham laser sessions.
3

All participants received first-line nonhormonal moisturizers and/or lubricants and vibrators, regardless of group assignment.
4

The primary endpoint was the between-group difference in change in Female Sexual Function Index total score from baseline to month 12.
5

Secondary outcomes included dyspareunia, sexual activity, body image, quality of life, vaginal health, objective vaginal measures, and safety.

1